Ziftomenib Maintenance Post Allo-HCT

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 6, 2024

Primary Completion Date

September 1, 2026

Study Completion Date

September 1, 2027

Conditions

Acute Myeloid LeukemiaAcute Myeloid Leukemia in RemissionNPM1 MutationKMT2A Rearrangement

Interventions

DRUG

Ziftomenib

Taken orally once per day

Trial Locations (1)

RECRUITING

Massachusetts General Hospital, Boston

All Listed Sponsors

lead

Massachusetts General Hospital

OTHER